Published in J Immunother on May 01, 2010
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med (2011) 5.54
Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med (2011) 4.91
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov (2013) 1.93
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
Is HCMV a tumor promoter? Virus Res (2010) 1.81
Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae (2010) 1.40
Th17 cells in cancer: the ultimate identity crisis. Front Immunol (2014) 1.33
The role IL-1 in tumor-mediated angiogenesis. Front Physiol (2014) 1.19
Tumour inflammasome-derived IL-1β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. EMBO Mol Med (2012) 1.14
Cancer and innate immune system interactions: translational potentials for cancer immunotherapy. J Immunother (2012) 1.05
Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer (2010) 1.04
Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. Curr Med Chem (2013) 0.97
Molecular mechanisms of tumor angiogenesis. Genes Cancer (2011) 0.96
Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther (2013) 0.95
Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clin Dev Immunol (2012) 0.92
Inflammation-based scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patients. Biomed Res Int (2014) 0.91
The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. ScientificWorldJournal (2012) 0.90
Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol (2015) 0.90
CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer. World J Gastroenterol (2012) 0.88
The human condition: an immunological perspective. Nat Immunol (2011) 0.88
Human serum-derived hydroxy long-chain fatty acids exhibit anti-inflammatory and anti-proliferative activity. J Exp Clin Cancer Res (2011) 0.88
A multi-targeted approach to suppress tumor-promoting inflammation. Semin Cancer Biol (2015) 0.87
Nuclear receptors as modulators of the tumor microenvironment. Cancer Prev Res (Phila) (2011) 0.87
Molecular alterations in glioblastoma: potential targets for immunotherapy. Prog Mol Biol Transl Sci (2011) 0.86
Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer. Breast Cancer Res Treat (2013) 0.86
The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. Radiat Res (2014) 0.86
Effects of different electroacupuncture scheduling regimens on murine bone tumor-induced hyperalgesia: sex differences and role of inflammation. Evid Based Complement Alternat Med (2012) 0.85
A role for T-lymphocytes in human breast cancer and in canine mammary tumors. Biomed Res Int (2014) 0.85
Pharmacological potential of biogenic amine-polyamine interactions beyond neurotransmission. Br J Pharmacol (2013) 0.84
Alterations of gene expression and protein synthesis in co-cultured adipose tissue-derived stem cells and squamous cell-carcinoma cells: consequences for clinical applications. Stem Cell Res Ther (2014) 0.84
Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage. Cancer Prev Res (Phila) (2015) 0.83
Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment. Nat Commun (2014) 0.83
Autoimmunity as a double agent in tumor killing and cancer promotion. Front Immunol (2014) 0.83
Perspectives in anaesthesia for cancer surgery. J Cancer Res Clin Oncol (2013) 0.82
Bioactive Compounds Isolated from Microalgae in Chronic Inflammation and Cancer. Mar Drugs (2015) 0.82
Considerations for successful cancer immunotherapy in aged hosts. Clin Exp Immunol (2016) 0.81
Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression. Oncol Lett (2013) 0.80
Effects of long-term oral administration of arachidonic acid and docosahexaenoic acid on the immune functions of young rats. Nutrients (2013) 0.79
Inflammatory response to liver fluke Opisthorchis viverrini in mice depends on host master coregulator MTA1, a marker for parasite-induced cholangiocarcinoma in humans. Hepatology (2011) 0.79
Timing and intensity of exposure to interferon-γ critically determines the function of monocyte-derived dendritic cells. Immunology (2014) 0.79
IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer. Front Oncol (2013) 0.79
Bacterial Heat Shock Protein Activity. J Clin Diagn Res (2016) 0.78
Prognostic role of the combination of platelet count and neutrophil-lymphocyte ratio in patients with hypopharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol (2016) 0.78
Cacospongionolide and scalaradial, two marine sesterterpenoids as potent apoptosis-inducing factors in human carcinoma cell lines. PLoS One (2012) 0.78
The inhibitory effect of a novel polypeptide fraction from Arca subcrenata on cancer-related inflammation in human cervical cancer HeLa cells. ScientificWorldJournal (2014) 0.78
Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours. Clin Sarcoma Res (2016) 0.77
Human breast cancer biopsies induce eosinophil recruitment and enhance adjacent cancer cell proliferation. Breast Cancer Res Treat (2016) 0.77
Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments. Cancer Gene Ther (2014) 0.77
Maslinic Acid enhances signals for the recruitment of macrophages and their differentiation to m1 state. Evid Based Complement Alternat Med (2015) 0.77
Cancer microenvironment, inflammation and cancer stem cells: A hypothesis for a paradigm change and new targets in cancer control. Surg Neurol Int (2015) 0.77
Gamma-glutamyl transferase and C-reactive protein as alternative markers of metabolic abnormalities and their associated comorbidites: a prospective cohort study. Int J Mol Epidemiol Genet (2012) 0.77
Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis. BJU Int (2012) 0.77
Regulatory T Cells Contribute to the Inhibition of Radiation-Induced Acute Lung Inflammation via Bee Venom Phospholipase A₂ in Mice. Toxins (Basel) (2016) 0.77
Promising development from translational or perhaps anti-translational research in breast cancer. Clin Transl Med (2012) 0.76
Melittin induces human gastric cancer cell apoptosis via activation of mitochondrial pathway. World J Gastroenterol (2016) 0.76
Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice. Cancer Immunol Res (2016) 0.76
TREM-1low is a novel characteristic for tumor-associated macrophages in lung cancer. Oncotarget (2016) 0.75
Soluble TNF Regulates TACE via AP-2α Transcription Factor in Mouse Dendritic Cells. J Immunol (2016) 0.75
The Relationship between Obesity, Prostate Tumor Infiltrating Lymphocytes and Macrophages, and Biochemical Failure. PLoS One (2016) 0.75
C-reactive protein as a prognostic factor in patients with chordoma of lumbar spine and sacrum-a single center pilot study. World J Surg Oncol (2016) 0.75
High IL-17 expression is associated with an unfavorable prognosis in thyroid cancer. Oncol Lett (2017) 0.75
Protective effect of a novel antibody against TLR2 on zymosan-induced acute peritonitis in NF-κB transgenic mice. Am J Transl Res (2017) 0.75
A Comparative Approach of Tumor-Associated Inflammation in Mammary Cancer between Humans and Dogs. Biomed Res Int (2016) 0.75
Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling. Oncotarget (2017) 0.75
Effects of PPARγ agonistrosiglitazone on human retinoblastoma cell in vitro and in vivo. Int J Clin Exp Pathol (2015) 0.75
Increased transforming growth factor β and interleukin 10 transcripts in peripheral blood mononuclear cells of colorectal cancer patients. Contemp Oncol (Pozn) (2017) 0.75
Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma. Cancer Med (2015) 0.75
HCMV-encoded miR-UL112-3p promotes glioblastoma progression via tumour suppressor candidate 3. Sci Rep (2017) 0.75
Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites. Theranostics (2017) 0.75
Brassica-Derived Plant Bioactives as Modulators of Chemopreventive and Inflammatory Signaling Pathways. Int J Mol Sci (2017) 0.75
Therapeutic potential of GW501516 and the role of Peroxisome proliferator-activated receptor β/δ and B-cell lymphoma 6 in inflammatory signaling in human pancreatic cancer cells. Biochem Biophys Rep (2016) 0.75
Immune responses triggering colitis and colitis-associated carcinoma. Langenbecks Arch Surg (2012) 0.75
Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study. Int J Mol Sci (2017) 0.75
The effects of nonsteroidal anti-inflammatory drugs in the incident and recurrent risk of hepatocellular carcinoma: a meta-analysis. Onco Targets Ther (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Inflammation and cancer. Nature (2002) 53.78
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Cancer-related inflammation. Nature (2008) 34.21
Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med (2000) 25.49
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007) 14.37
Toll-like receptors in innate immunity. Int Immunol (2005) 12.24
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell (2006) 11.79
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol (2005) 11.57
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol (2006) 10.73
Stromal gene expression predicts clinical outcome in breast cancer. Nat Med (2008) 10.68
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 9.29
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature (2000) 8.96
TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet (2000) 8.79
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med (2003) 6.99
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res (2007) 6.60
Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res (2006) 6.52
CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res (1998) 6.42
Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med (2006) 6.15
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med (1993) 6.13
Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev (1999) 6.10
Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell (2006) 5.97
Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) (2008) 5.82
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell (2005) 5.79
The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med (2008) 5.74
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62
Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol (2007) 5.28
Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol (2004) 5.13
Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity (2009) 5.10
Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol (2009) 4.74
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev (2002) 4.63
Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell (2008) 4.43
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 4.43
Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity (2008) 4.37
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell (2004) 4.23
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med (1996) 4.11
MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci U S A (2009) 3.97
HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature (2009) 3.86
Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology (2003) 3.58
MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum (2009) 3.44
The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res (2007) 3.35
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology (2006) 3.35
The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev (2007) 3.33
The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev (2008) 3.33
miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta (2009) 3.28
Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology (2008) 3.25
Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res (2004) 2.95
Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology (2001) 2.89
Friendly and dangerous signals: is the tissue in control? Nat Immunol (2007) 2.87
Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol (2005) 2.85
Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol (2007) 2.81
Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol (2005) 2.78
IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol (2009) 2.64
RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med (2009) 2.56
In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med (1999) 2.54
Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res (2007) 2.49
Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol (1996) 2.44
Masquerader: high mobility group box-1 and cancer. Clin Cancer Res (2007) 2.40
A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology (2003) 2.39
Induction of host signal transduction pathways by Helicobacter pylori. Proc Natl Acad Sci U S A (1997) 2.38
MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci U S A (2009) 2.36
Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res (2004) 2.34
Recent advances in chemoprevention of cancer. Science (1997) 2.30
The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ (2009) 2.30
Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med (2007) 2.25
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res (2007) 2.15
TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A (2006) 2.14
Why cancer and inflammation? Yale J Biol Med (2006) 2.13
The importance of interleukin 1beta in Helicobacter pylori associated disease. Gut (2001) 2.02
A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology (2006) 1.98
Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. J Immunol (2003) 1.96
Polarized immune responses differentially regulate cancer development. Immunol Rev (2008) 1.95
Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res (2004) 1.91
Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother (2004) 1.88
Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol (2005) 1.87
Interleukin 1 beta and tumour necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut (1998) 1.82
MicroRNAs impair MET-mediated invasive growth. Cancer Res (2008) 1.81
Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res (2005) 1.77
A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res (2004) 1.73
Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol (2005) 1.66
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst (2007) 1.65
Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer (2005) 1.63
Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol (1999) 1.58
The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res (2004) 1.55
Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer (2000) 1.51
Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat Res (2006) 1.47
In vivo profile of the human leukocyte microRNA response to endotoxemia. Biochem Biophys Res Commun (2009) 1.45
Immunity, inflammation, and cancer. Cell (2010) 28.27
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83
A central role for JNK in obesity and insulin resistance. Nature (2002) 17.27
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut (2012) 12.62
Cancer immunotherapy comes of age. Nature (2011) 12.35
IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med (2005) 12.07
Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol (2009) 11.76
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol (2004) 10.85
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
AP-1 as a regulator of cell life and death. Nat Cell Biol (2002) 10.10
Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell (2005) 9.16
Plasmacytoid dendritic cells in immunity. Nat Immunol (2004) 9.11
Regulation and function of IKK and IKK-related kinases. Sci STKE (2006) 8.98
IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell (2005) 8.78
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54
microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24
Intracellular pattern recognition receptors in the host response. Nature (2006) 8.04
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 7.86
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell (2008) 6.88
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell (2008) 6.83
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67
Tumor stroma and regulation of cancer development. Annu Rev Pathol (2006) 6.66
Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov (2009) 6.36
Inflammation and colon cancer. Gastroenterology (2010) 6.32
Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol (2011) 6.17
NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature (2008) 6.13
Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell (2005) 5.79
Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature (2005) 5.72
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol (2002) 5.39
The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity (2002) 5.38
JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab (2007) 5.38
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science (2005) 5.25
The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell (2006) 5.18
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09
Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol (2006) 5.00
Interleukin-17 promotes angiogenesis and tumor growth. Blood (2002) 4.90
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
NF-κB and the link between inflammation and cancer. Immunol Rev (2012) 4.74
Endogenous HMGB1 regulates autophagy. J Cell Biol (2010) 4.71
Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature (2007) 4.68
Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med (2002) 4.67
NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev (2008) 4.61
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell (2007) 4.56
Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53
Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell (2003) 4.50
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature (2012) 4.41
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 4.33
IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature (2005) 4.31
Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev (2002) 4.30
An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell (2011) 4.29
Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet (2011) 4.26
Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science (2002) 4.26
Compartmentalized control of skin immunity by resident commensals. Science (2012) 4.19
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med (2005) 4.11
NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10
Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature (2011) 4.07
IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest (2005) 4.07
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00
Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell (2004) 3.98
Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell (2004) 3.94
miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther (2007) 3.93
The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med (2002) 3.91
Cancer: an inflammatory link. Nature (2004) 3.88
Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science (2010) 3.86
Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J Exp Med (2002) 3.86
The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med (2003) 3.85
FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell (2010) 3.80
Laser-capture microdissection. Nat Protoc (2006) 3.80
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med (2005) 3.80
Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res (2007) 3.76
A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery. Mol Cell (2004) 3.71
Inflammation and necrosis promote tumour growth. Nat Rev Immunol (2004) 3.68
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med (2008) 3.68
Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science (2004) 3.66
A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med (2005) 3.59
Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell (2008) 3.58
Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem (2005) 3.56
Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature (2011) 3.56
Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med (2004) 3.55